DOI:
10.1055/s-00000140
Pädiatrie up2date
LinksClose Window
References
Haas M, Vlcek V, Balabanov P. et al.
European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.
Neuromuscul Disord 2015;
1: 5-13
doi:10.1016/j.nmd.2014.11.011
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.